AGN - Allergan plc

NYSE - Nasdaq Real Time Price. Currency in USD
150.38
-1.89 (-1.24%)
As of 2:51PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close152.27
Open152.28
Bid150.23 x 1000
Ask150.31 x 800
Day's Range150.20 - 153.38
52 Week Range142.81 - 197.00
Volume726,346
Avg. Volume2,182,878
Market Cap50.721B
Beta (3Y Monthly)1.34
PE Ratio (TTM)22.90
EPS (TTM)6.57
Earnings DateFeb 4, 2019 - Feb 8, 2019
Forward Dividend & Yield2.88 (1.85%)
Ex-Dividend Date2018-11-09
1y Target Est212.28
Trade prices are not sourced from all markets
  • Zacks6 hours ago

    Bausch (BHC) Bids for Assets of Synergy Pharmaceuticals

    Bausch (BHC) bids to acquire certain assets of Synergy Pharma for $200 million.

  • Is Allergan plc (AGN) A Good Stock To Buy?
    Insider Monkey4 days ago

    Is Allergan plc (AGN) A Good Stock To Buy?

    Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed over the past few years. However, hedge funds are generally partially hedged and […]

  • Okta (OKTA) Q3 Earnings and Revenues Surpass Estimates
    Zacks7 days ago

    Okta (OKTA) Q3 Earnings and Revenues Surpass Estimates

    Okta's (OKTA) third-quarter fiscal 2019 results benefit from increasing adoption of the company's Identity solutions.

  • Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger
    Zacks7 days ago

    Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger

    Shire's (SHPG) pending acquisition by Takeda Pharmaceuticals for $62 billion gets approval from shareholders of both the companies.

  • Bausch’s Ultra Multifocal Contact Lenses Get FDA Approval
    Market Realist7 days ago

    Bausch’s Ultra Multifocal Contact Lenses Get FDA Approval

    On December 5, Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies, announced that the US FDA provided 510(K) clearance for its Ultra multifocal contact lenses for use in patients with astigmatism. The Ultra multifocal toric lens will be the first of its kind available for standard use.

  • David Tepper's Top 5 Holdings
    GuruFocus.com8 days ago

    David Tepper's Top 5 Holdings

    Guru’s top holding as of the 3rd quarter is semiconductor manufacturer Micron Technology

  • Ride the Wellness Wave at Sea with Shares of this Unique Spa Operator
    IPO-Edge.comlast month

    Ride the Wellness Wave at Sea with Shares of this Unique Spa Operator

    One Spa World to Go Public through Merger with Haymaker Acquisition Corp By John Jannarone The cruise industry is sometimes fraught with dangerous waters. But now, investors have a better way to navigate them. Meet One Spa World (OSW), the dominant health and wellness company that operates spas aboard major cruise lines such as Carnival […]

  • Ride the Wellness Wave at Sea with Shares of this Unique Spa Operator
    IPO Edgelast month

    Ride the Wellness Wave at Sea with Shares of this Unique Spa Operator

    One Spa World to Go Public through Merger with Haymaker Acquisition Corp By John Jannarone The cruise industry is sometimes fraught with dangerous waters. But now, investors have a better way to navigate them. Meet One Spa World (OSW), the dominant health and wellness company that operates spas aboard major cruise lines such as Carnival […]

  • GuruFocus.com12 days ago

    Stocks That Fell to 3-Year Lows in the Week of Nov. 30

    Allergan PLC (ACT), Schlumberger Ltd. (SLB), General Mills Inc. (GIS) and Noble Energy Inc. (NBL) have declined to their 3-year lows

  • ICR Hires BlackRock Executive to Lead Governance Advisory Solutions Group
    CorpGov.comlast month

    ICR Hires BlackRock Executive to Lead Governance Advisory Solutions Group

    Lyndon Park Joins ICR as Managing Director, Head of Governance Advisory Solutions By John Jannarone ICR has hired Lyndon Park, a former executive at BlackRock and Dimensional Fund Advisors, to lead its newly-launched Governance Advisory Solutions practice, the communications and advisory firm announced Thursday. The new group, which ICR established as it hired Mr. Park, […]

  • Zacks Small Cap Research13 days ago

    EYEG: Is EyeGate Eyeing FDA Filings Following Positive OBG Data in Both PRK and PE?

    EyeGate (EYEG) announced Q3 financial results and provided a business update. To-date, EYEG has received $13.8M in upfront and milestones under the two agreements, including ~$300k in the most recent quarter. While the yoy decrease reflects a change in activity from the relatively large EGP-437 trials to the smaller OBG studies, the qoq increase is a result of continued progression of both OBG programs.

  • GlobeNewswire13 days ago

    Recent Analysis Shows Applied Optoelectronics, J.M. Smucker, RYB Education, Inc. Sponsored ADR, Workiva, Bilibili Inc. Sponsored ADR, and Allergan plc Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • A Pharmaceutical Company With a Resilient Portfolio and Solid Pipeline
    GuruFocus.com14 days ago

    A Pharmaceutical Company With a Resilient Portfolio and Solid Pipeline

    Allergan PLC (AGN) is one of the largest specialty pharmaceutical manufacturers. It specializes in aesthetics, ophthalmology, women's health, gastrointestinal and central nervous system products. In 2016, Allergan sold its generics and distribution segments to Teva Pharmaceutical Industries Ltd. (TEVA).

  • A Look at Celgene’s Revlimid Label Expansion Initiatives in 2018
    Market Realist14 days ago

    A Look at Celgene’s Revlimid Label Expansion Initiatives in 2018

    On December 22, 2015, Celgene (CELG) issued a press release announcing the settlement of patent litigation for Revlimid with Natco Pharma, Arrow International, and parent company Watson Laboratories, which was then a wholly owned subsidiary of Allegan (AGN). Currently, Watson Laboratories is a part of Teva Pharmaceuticals (TEVA).

  • 5 Biotech Stocks to Scoop Up for Big Dividends
    InvestorPlace16 days ago

    5 Biotech Stocks to Scoop Up for Big Dividends

    When it comes to biotech stocks, the perception is that the sector is a gamble. Many investors believe that most biotech stocks are clinical-stage lotto tickets that will only succeed on a wish and a prayer. It’s here that investors can find stable cash flows, profits, and even dividend stocks.

  • Spinal-cord stimulators help some patients, injure others
    Associated Press17 days ago

    Spinal-cord stimulators help some patients, injure others

    Desperate for relief after years of agony, Jim Taft listened intently as his pain management doctor described a medical device that could change his life. Taft's stimulator failed soon after it was surgically implanted. For years, medical device companies and doctors have touted spinal-cord stimulators as a panacea for millions of patients suffering from a wide range of pain disorders, making them one of the fastest-growing products in the $400 billion medical device industry.

  • Breast implants reveal problems in tracking device safety
    Associated Press17 days ago

    Breast implants reveal problems in tracking device safety

    WASHINGTON (AP) — To all the world, it looked like breast implants were safe. From 2008 to 2015, the U.S. Food and Drug Administration publicly reported 200 or so complaints annually — a tiny fraction of the hundreds of thousands of implant surgeries performed each year.

  • 3 Stocks That Are Absurdly Cheap Right Now
    Motley Fool17 days ago

    3 Stocks That Are Absurdly Cheap Right Now

    If you got trampled during a Black Friday sale and had to return home without wares, these three bargain stocks will make you feel better. Waiting in line not required.

  • PR Newswire17 days ago

    Allergan Makes New Appointments to Finance Leadership Team

    DUBLIN, Nov. 26, 2018 /PRNewswire/ -- Allergan plc (AGN), a leading global biopharmaceutical company, today announced that Daphne Karydas will take on the new role of Senior Vice President Corporate Financial Planning & Analysis and Strategy, and Manisha Narasimhan, PhD, will join the Company as Vice President of Investor Relations and Strategic Initiatives, effective December 10, 2018.

  • CNBC22 days ago

    Hedge funds are in a 'vicious downward cycle' as their favorite stocks badly trail market

    The most popular long positions at 823 hedge funds have lagged the S&P 500 by 7 percentage points since mid-June, according to Goldman Sachs. Headwinds have brought the average equity hedge fund year-to-date loss to 4 percent, Goldman says. The S&P 500 is down 0.2 percent in 2018.

  • FDA Accepts Allergan's (AGN) sNDA for Anti-Infective Avycaz
    Zacks22 days ago

    FDA Accepts Allergan's (AGN) sNDA for Anti-Infective Avycaz

    The FDA accepts Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.

  • PR Newswire23 days ago

    Allergan to Present at the 2018 Citi Global Healthcare Conference

    DUBLIN , Nov. 20, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the ...

  • PR Newswire23 days ago

    Allergan Announces FDA Acceptance of Supplemental New Drug Application for AVYCAZ® (ceftazidime and avibactam)

    - Application Seeks to Expand the AVYCAZ label to Include Treatment of cUTI and cIAI in Pediatric Patients 3 months of age and older - DUBLIN , Nov. 20, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today ...

  • Morningstar23 days ago

    Our Ultimate Stock-Pickers Top 10 New-Money Purchases

    For the past nine years, our primary goal with the Ultimate Stock-Pickers concept has been to uncover investment ideas that reflect the most recent transactions of our grouping of top investment managers in a timely enough manner for investors to get some value from them. In cross-checking the most current valuation work and opinions of Morningstar's own cadre of stock analysts against the actions of some of the best equity managers in the business, we hope to uncover a few good ideas each quarter that investors can dig into a bit deeper to see if they warrant an investment. With 25 out of our 26 Ultimate Stock-Pickers having reported their holdings for the third quarter of 2018, we now have a good sense of what stocks piqued their interest during the period.

  • The regulatory impact on biotech and health care stocks
    CNBC Videos24 days ago

    The regulatory impact on biotech and health care stocks

    Ronny Gal, Bernstein analyst, discusses what investors should expect from biotech and health care stocks in the final part of 2018.